Related references
Note: Only part of the references are listed.Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
Giovanni Palladini et al.
BLOOD (2020)
Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol
Issam S. Hamadeh et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
Maria-Victoria Mateos et al.
LANCET HAEMATOLOGY (2020)
ENHANZE((R)) drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase 20
Kenneth W. Locke et al.
DRUG DELIVERY (2019)
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Ninety-minute daratumumab infusion is safe in multiple myeloma
Hallie Barr et al.
LEUKEMIA (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
X. S. Xu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
Eli Muchtar et al.
BLOOD (2017)
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
Larysa Sanchez et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration
Sanna Rosengren et al.
AAPS JOURNAL (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A recombinant human enzyme for enhanced interstitial transport of therapeutics
L. H. Bookbinder et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Share Paper
